| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00198-010-1320-4 |
| P698 | PubMed publication ID | 20552327 |
| P50 | author | Lars Rejnmark | Q43231283 |
| P2093 | author name string | P Vestergaard | |
| L Mosekilde | |||
| P2860 | cites work | Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension in the Adult US Population : Data From the Health Examination Surveys, 1960 to 1991 | Q22306381 |
| The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men | Q24658075 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| The Danish National Hospital Register. A valuable source of data for modern health sciences. | Q31380260 | ||
| Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells | Q32139468 | ||
| Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study | Q33146441 | ||
| Alcohol intake as a risk factor for fracture | Q33981937 | ||
| Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia | Q35157640 | ||
| State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. | Q35982334 | ||
| Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies | Q36589348 | ||
| The national patient registry. Evaluation of data quality | Q36689291 | ||
| Etiology, epidemiology, and natural history of benign prostatic hyperplasia | Q37639586 | ||
| Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis | Q40768242 | ||
| Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark | Q43532110 | ||
| Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia | Q43754275 | ||
| The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial | Q43961475 | ||
| Comparative study of modified release alpha-blocker exposure in elderly patients with fractures | Q44349278 | ||
| Association between 5-alpha reductase inhibition and risk of hip fracture | Q44561412 | ||
| Use of alpha-blockers and the risk of hip/femur fractures. | Q44671122 | ||
| Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark | Q44936854 | ||
| Fracture risk associated with use of antiepileptic drugs | Q45127644 | ||
| [The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia]. | Q45985217 | ||
| Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study | Q46935516 | ||
| The Danish Psychiatric Central Register. | Q47333462 | ||
| Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. | Q50571371 | ||
| Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. | Q53811664 | ||
| Altered extracellular calcium homoeostasis in essential hypertension: A consequence of abnormal cell calcium handling | Q57368645 | ||
| Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism | Q67467248 | ||
| Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study | Q74720363 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostatic hypertrophy | Q506659 |
| P304 | page(s) | 731-737 | |
| P577 | publication date | 2010-06-15 | |
| P1433 | published in | Osteoporosis International | Q7107640 |
| P1476 | title | Risk of fractures associated with treatment for benign prostate hyperplasia in men | |
| P478 | volume | 22 |
| Q55380284 | A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. |
| Q34395346 | Androgens and estrogens in skeletal sexual dimorphism. |
| Q49538209 | Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study |
| Q35808841 | Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study |
| Q36243696 | Risk of hip/femur fractures during the initiation period of α-adrenoceptor blocker therapy among elderly males: a self-controlled case series study |
| Q36206485 | The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study |
Search more.